ESOPHAGEAL CANCER NEWS TIPS & FEATURES


OMNI Health Media is a leading online provider of Daily Health News. OMNI’s Recurrent Gastric Cancer News provides summaries of developments in the prevention, screening, and management of Gastrointestinal Health Conditions as they are discovered and reported by physicians and scientists around the world. Our mission is to provide this news, including results of recent clinical trials evaluating new therapies and supportive care strategies in order to better educate patients and their caregivers, ensuring timely access to the best care available.
Proton Beam Therapy May Improve Outcomes for Esophageal Cancer

January 23rd, 2017

Proton Beam Therapy May Improve Outcomes for Esophageal Cancer

By Anonymous User anonymous_user_10987

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for select cancers of the esophagus, anus, rectum, pancreatic, or small intestine. This treatment approach is often associated with improved outcomes but the radiation may also cause […]

View full entry

Tags: Esophageal Cancer, Gastric Cancer, News Tips and Features, News Tips and Features Other, Pancreatic Cancer, proton beam therapy, Recurrent Gastric Cancer, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage IV/Recurrent Esophageal Cancer, Stages I-II Gastric Cancer, Stages I-III Esophageal Cancer


IMAB362 Leads to Longer Remission and Better Survival in Gastric Cancer

June 6th, 2016

IMAB362 Leads to Longer Remission and Better Survival in Gastric Cancer

By Anonymous User anonymous_user_10987

The results of a novel treatment for gastric cancer with the investigational antibody IMAB362 were released at the American Society of Clinical Oncology (ASCO) this week. IMAB362 led to extended remissions and prolonged survival for patients with advanced gastric cancers. Gastric cancer refers to cancer of the stomach. The American Cancer Society estimates that 24,590 […]

View full entry

Tags: 2016, antibody, asco, capecitabine, claudin, Ellence, eloxatin, epirubicin, Gastric Cancer, gastric tumors, IMAB362, longer remission


Afinitor® Promising in Neuroendocrine Tumors Originating in Gastrointestinal Tract or Lungs

August 10th, 2015

Afinitor® Promising in Neuroendocrine Tumors Originating in Gastrointestinal Tract or Lungs

By Anonymous User anonymous_user_10987

The drug Afinitor® (everolimus) is currently be studied in a Phase III clinical trial for patients with nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract or lungs. The trial is ongoing, but findings so far are promising: patients treated with Afinitor plus best supportive care appear to live longer without cancer progression than patients […]

View full entry

Tags: afinitor, everolimus, Gastric Cancer, General Lung Cancer, Lung Cancer, mtor, NET, neuroendocrine tumors, News Tips and Features, News Tips and Features Other, Recurrent Gastric Cancer, Stages III-IV Gastric Cancer


U.S. FDA Issues Warning about Certain Type of Endoscope

February 20th, 2015

U.S. FDA Issues Warning about Certain Type of Endoscope

By Anonymous User anonymous_user_10987

The U.S. Food and Drug Administration (FDA) has issued a Safety Communication about a certain type of endoscope­—specifically the device used in endoscopic retrograde cholangiopancreatography (ERCP). According to the FDA, the device may be difficult to clean effectively and may spread dangerous bacteria among patients. An endoscope is thin, tube-like instrument that’s used to look […]

View full entry

Tags: cancer screening, endoscope, fda, fda warning, Gastric Cancer, News Tips and Features, News Tips and Features Other, Recurrent Gastric Cancer, Screening/Prevention Gastric Cancer, Stages I-II Gastric Cancer, Stages III-IV Gastric Cancer


AMG 337 MET Inhibitor Produces Impressive, Rapid Response in Gastric and Esophageal Cancers

February 12th, 2015

AMG 337 MET Inhibitor Produces Impressive, Rapid Response in Gastric and Esophageal Cancers

By Anonymous User anonymous_user_10987

AMG 337 is a novel small-molecule MET inhibitor that appears to show promise in the treatment of MET-amplified gastroesophageal junction, gastric, and esophageal cancers. MET inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase. These inhibitors may have therapeutic application in the treatment of various types of […]

View full entry

Tags: AMG 337, Esophageal Cancer, esophagus, Gastric Cancer, gastroesophageal junction, gastrointestinal cancer, GI tumors, MET inhibitor, News Tips and Features, News Tips and Features Other, Recurrent Gastric Cancer, Stage IV/Recurrent Esophageal Cancer


FDA Approves Cyramza™ in Combination With Paclitaxel for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

November 13th, 2014

FDA Approves Cyramza™ in Combination With Paclitaxel for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

By Anonymous User anonymous_user_10987

(CancerConnect) The U.S. Food and Drug Administration(FDA) has approved Cyramza™ (ramucirumab) for use in combination with paclitaxel for the treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma. Cyramza was approved in April 2014 as a single agent for the treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma refractory to or progressive […]

View full entry

Tags: cyramza, Esophageal Cancer, Gastric Cancer, News Tips and Features, News Tips and Features Other, paclitaxel, Recurrent Gastric Cancer, Stage IV/Recurrent Esophageal Cancer, Stages III-IV Gastric Cancer


Apatinib Prolongs Survival in Advanced Gastric Cancer

June 26th, 2014

Apatinib Prolongs Survival in Advanced Gastric Cancer

By Anonymous User anonymous_user_10987

Apatinib significantly improved overall survival according to the results of a phase III study presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Gastric cancer refers to cancer of the stomach. Though gastric cancer has a relatively low incidence in the United States, it is the second leading cause of […]

View full entry

Tags: apatinib, Gastric Cancer, News Tips and Features, News Tips and Features Other, Recurrent Gastric Cancer, Stages III-IV Gastric Cancer


Ramucirumab Plus Paclitaxel Improves Survival in Metastatic Gastric Cancer

February 21st, 2014

Ramucirumab Plus Paclitaxel Improves Survival in Metastatic Gastric Cancer

By Anonymous User anonymous_user_10987

Ramucirumab significantly improved both progression-free and overall survival, when added to paclitaxel in second-line therapy for metastatic gastric cancer, according to the results of a study presented at the 2014 Gastrointestinal Cancers Symposium. Gastric cancer refers to cancer of the stomach. Though gastric cancer has a relatively low incidence in the United States, it is […]

View full entry

Tags: Gastric Cancer, News Tips and Features, News Tips and Features Other, ramucirumab, Recurrent Gastric Cancer, Stages III-IV Gastric Cancer


View more articles like this
More news and in-depth Gastric Cancer information

CONDITIONS OF THE GI TRACT